Next Article in Journal
May the Force (Field) Be with You: On the Importance of Conformational Searches in the Prediction of NMR Chemical Shifts
Next Article in Special Issue
Natural Products from Chilean and Antarctic Marine Fungi and Their Biomedical Relevance
Previous Article in Journal
Comparison of Growth and Chemical Profile of Diatom Skeletonema grevillei in Bioreactor and Incubation-Shaking Cabinet in Two Growth Phases
Previous Article in Special Issue
New Alkylpyridinium Anthraquinone, Isocoumarin, C-Glucosyl Resorcinol Derivative and Prenylated Pyranoxanthones from the Culture of a Marine Sponge-Associated Fungus, Aspergillus stellatus KUFA 2017
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 20
Issue 11
10.3390/md20110698
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Noonindoles A–F: Rare Indole Diterpene Amino Acid Conjugates from a Marine-Derived Fungus, Aspergillus noonimiae CMB-M0339

by
Sarani Kankanamge
1,
Zeinab G. Khalil
1,
Paul V. Bernhardt
2 and
Robert J. Capon
1,*
1
Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia
2
School of Chemistry and Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia
*
Author to whom correspondence should be addressed.
Mar. Drugs 2022, 20(11), 698; https://doi.org/10.3390/md20110698
Submission received: 18 October 2022 / Revised: 31 October 2022 / Accepted: 4 November 2022 / Published: 7 November 2022
(This article belongs to the Special Issue Bioactive Secondary Metabolites of Marine Fungi)
Browse Figures
Versions Notes

Abstract

:
Analytical scale chemical/cultivation profiling prioritized the Australian marine-derived fungus Aspergillus noonimiae CMB-M0339. Subsequent investigation permitted isolation of noonindoles A–F (5–10) and detection of eight minor analogues (i–viii) as new examples of a rare class of indole diterpene (IDT) amino acid conjugate, indicative of an acyl amino acid transferase capable of incorporating a diverse range of amino acid residues. Structures for 5–10 were assigned by detailed spectroscopic and X-ray crystallographic analysis. The metabolites 5–14 exhibited no antibacterial properties against G-ve and G+ve bacteria or the fungus Candida albicans, with the exception of 5 which exhibited moderate antifungal activity.

Graphical Abstract

1. Introduction

Since the indole diterpene (IDT) paxilline (1) (Figure 1) was first described in 1975 as a tremorgenic agent of Penicillium paxilli [1], a number of fungal natural products sharing this fused hexacyclic skeleton have been reported (i.e., paxillines, paspalines, paspalinines, paspalicine, paspalitrems, penijanthine A, penitrems, aflatrem, penerpenes, sulpinines, and terpendoles) from a wide range of genera, including from terrestrially sourced Acremonium [2], Albophoma [3,4,5], Aspergillus [6,7,8,9,10], Chaunopycnis [11], Claviceps [12], Emericella [13,14], Eupenicillium [15], Neotyphodium [16], Penicillium [2,17,18,19,20,21], Phomopsis [22], and marine-derived Penicillium [23,24,25,26,27]. In addition to tremorgenic properties [1,2,6,7,13,14,17,22,28], members of this IDT family have been reported to exhibit anticancer [23,29], anti-insectan [8,9,15] and anti-H1N1 [24] activity, with Merck researchers reporting potent and selective potassium ion channel antagonist properties [28] prompting patent protection for the treatment of neurodegenerative diseases (i.e., Alzheimer’s disease) [30] and glaucoma [31]. Paxilline (1) has been noted as one of the most potent and selective nonpeptidergic inhibitors of large-conductance, voltage, and Ca2+dependent BK-type potassium channels [32], stimulating interest in chemical synthesis [33,34,35] and biosynthesis [36,37,38,39,40,41,42] across this structure class. For example, a 2022 report [43] described two genes encoding monomodular nonribosomal peptide synthetase (NRPS)-like enzymes that catalyse the acylation of 14-hydroxypaspalinine (2) (Figure 1) to the only two known natural product examples of amino acid conjugated IDTs: 14-(N,N-dimethyl-L-valyloxy)paspalinine (3) (Figure 1) reported [9] in 1993 from Aspergillus nominus NRRL 13,137 and patented in 1993 as an anti-insectan for controlling Coleopteran and Lepidopteran insects [44], and in 2003 for the treatment of glaucoma [31]; and 14-(N,N-dimethyl-l-leucyloxy)paspalinine (4) patented in 2003 for the treatment of glaucoma [31] and subsequently optimised for production from Aspergillus alliaceus [10].
This current report describes our discovery of new IDT amino acid conjugates produced by the Australian marine-derived fungus Aspergillus noonimiae CMB-M0339. Using an integrated strategy of chemical and cultivation profiling to both prioritize and facilitate production, we successfully detected, isolated, characterised, and identified five new IDT amino acid conjugates and a key hydroxy precursor, noonindoles A–F (5–10), together with the four known analogues paspaline (11) [12], paspaline B (12) [18], the carboxylic acid (13) [24], and emindole SB (14) [13]. Structures for 5–14 were assigned by detailed spectroscopic and X-ray analysis as summarised below, along with a plausible biogenetic relationship. We also made use of biosynthetic considerations and diagnostic MS/MS fragmentations to tentatively assign structures to a series of eight minor IDT amino acid co-metabolites (i–viii).

2. Results

An EtOAc extract was prepared from a 3.3% saline M1 agar plate cultivation of the marine-derived fungus Aspergillus noonimiae CMB-M0339. UPLC-DAD (Figure S6) was subjected to a global natural product social (GNPS) [45] molecular network (Figure 2) analysis to reveal peaks/nodes for three prominent and structurally related metabolites: 5 (m/z 579 (M+H), C34H46N2O6); 6 (m/z 565 (M+H), C33H44N2O6); and 7 (m/z 593 (M+H), C35H48N2O6). Online database searching suggested these metabolites were unprecedented in the natural products literature. Subsequent cultivation profiling using a miniaturized 24-well plate microbioreactor methodology (MATRIX) [46] employing ×11 different media under solid agar (2 mL), as well as static and shaken broth (1.5 mL) conditions (Figure S7) supported by UPLC-DAD and GNPS chemical profiling (Figure 3 and Figure S8) confirmed D400 solid phase agar as the optimal culture condition. The EtOAc extract of a ×300 plate D400 solid phase 12 day cultivation was subjected to solvent trituration and reversed-phase HPLC (Figure S9) to yield 5–14 (Figure 4). Detailed spectroscopic analysis successfully identified the known natural products paspaline (11) [12], paspaline B (12) [18], the carboxylic acid 13 [24], and emindole SB (14) [13] (Tables S8–S11, Figures S50–S68). Further spectroscopic analysis identified the new noonindoles A–F (5–10) as summarised below.
HRESIMS analysis of 5 revealed a molecular formula (C34H46N2O6, Δmmu +2.7) requiring thirteen double bond equivalents (DBE). The NMR (methanol-d4) data for 5 (Table 1 and Table S2, and Figures S10–S15) disclosed resonances for ten sp2 olefinic carbons and two sp2 ester/lactone carbonyls, accounting for seven DBE and requiring that 5 be hexacyclic, while diagnostic 2D NMR correlations (Figure 5) established a carbon/hetero skeleton in common with 1 further annotated by an N,N-dimethyl-valinyloxy ester pendant to C-14. The structure and absolute configuration for noonindole A (5) were confirmed by a single crystal X-ray analysis (Figure 6 and Table S13).
HRESIMS analysis of 6–8 revealed molecular formulae (C33H44N2O6, Δmmu +2.0; C35H48N2O6, Δmmu +2.6; C33H44N2O6, Δmmu +1.5) consistent with lower/higher homologues of 5. Comparison of the NMR (methanol-d4) data for 6 (Table 1 and Table S3, Figures S17–S22) with 5 allowed the principle differences to be attributed to replacement of the N,N-dimethyl-valinyloxy side chain in 5 (δH 2.90, s; δC 43.1) with an N-methyl-valinyloxy side chain in 6 (δH 2.72, s, NH(CH3); δC 33.8, NH(CH3)). Likewise, comparison of the NMR (methanol-d4) data for 7 (Table 1 and Table S4, and Figures S24–S29) and 8 (Table 2 and Table S5, and Figures S31–S35) with 5 allowed the principle differences to be attributed to replacement of the N,N-dimethyl-valinyloxy moiety in 5 with an N,N-dimethyl-leucinyloxy moiety in 7 and an N,N-dimethyl-homoalaninyloxy in 8. These conclusions were reinforced by diagnostic 2D NMR correlations (Figure 5) which, together with biogenetic considerations, allowed assignment of structures to noonindoles B–D (6–8).
HRESIMS analysis of 9 revealed a molecular formula (C34H44N2O6, Δmmu +1.2) consistent with an oxidised analogue of 5. Comparison of the NMR (methanol-d4) data for 9 (Table 2 and Table S6, and Figures S37–S41) with 5 allowed the principle differences to be attributed to replacement of the sp3 H-7/C- 7 methine in 5 (δH 4.91, H-7; δC 74.6, C-7) with an sp2 quaternary C-7 and sp2 H-6/C-6 methine in 9 (δH 5.74, m, H-6; δC 113.5, C-6; δC 146.4, C-7), consistent with incorporation of a Δ6,7. These conclusions were reinforced by 2D NMR correlations (Figure 5) which, together with biogenetic considerations, allowed assignment of the structure for noonindole E (9).
HRESIMS analysis of 10 revealed a molecular formula (C27H33NO5, Δmmu +1.1) consistent with a hydrolysed analogue of 5 lacking the N,N-dimethyl-valinyloxy ester side chain. This hypothesis was confirmed on comparison of the NMR (methanol-d4) data for 10 (Table 2 and Table S7, and Figures S43–S48) with 5 which revealed the absence of resonances for the N,N-dimethyl-valinyloxy moiety and a significant shielding of the resonance for H-14 in 10 (δH 4.16) compared with 5 (δH 5.53). These conclusions were reinforced by 2D NMR correlations (Figure 5) which, together with biogenetic considerations, allowed assignment of a structure for noonindole F (10).
Co-isolation of noonindoles A–F (5–10) and the known IDTs 11–14 together with an X-ray crystal analysis of 5 supported a common absolute configuration across the hexacyclic indole terpene core, and established the configuration of the N,N-dimethyl-l-valinyloxy moiety in 5. Although low yields combined with N-alkylation precluded hydrolysis and independent assignment of the amino acid residue absolute configuration in 6–9 (i.e., Marfey’s analysis), an amino acid l configuration across 6–9 was proposed based on the likelihood of a common NRPS-like aminoacyl modifying enzyme in the noonindole biosynthetic gene cluster (BGC) (see below).
The metabolites 5–14 did not inhibit the growth of human colon (SW620) or lung (NCI-H460) carcinoma cells (IC50 > 30 μM) (Figure S81), or the fungus Candida albicans ATCC10231, the Gram-negative bacterium Escherichia coli ATCC11775, or the Gram-positive bacteria Staphylococcus aureus ATCC25923 or Bacillus subtilis ATCC6633 (IC50 > 30 μM), with the exception of noonindole A (5) which displayed modest antifungal activity (IC50~5 μM) (Figure S80). This lack of cellular toxicity bodes well for future (ongoing) evaluation of noonindole ion channel inhibitory pharmacology.
GNPS analysis of the EtOAc extract of the analytical scale D400 (MATRIX) culture of CMB-M0339 detected 5–9 along with associated nodes for a selection of putative minor analogues (Figure 7). The MS/MS spectra for 5–9 (Figures S72–S75) revealed three common fragmentations attributed to loss of water (Figure 8A), retro-Aldol loss of acetone (Figure 8B), and loss of the amino acid residue (Figure 8C). While low yields precluded isolation of the minor analogues i–viii, diagnostic MS/MS fragmentations and high-resolution mass measurements (i.e., molecular formulae) permitted tentative assignments for i–v (Figures S74, S76–S79, Table S12) and on the basis of GNPS co-clustering and biosynthetic considerations to vi–viii, albeit with some allowance isomeric alternatives (Table 3 and Table S12). The diversity of IDT amino acid conjugates produced by CMB-M0339 is in stark contrast to existing knowledge, which is limited to 3 from Aspergillus nomius [9] and 4 from A. alliaceus [10]. Unlike these earlier published accounts, it appears CMB-M0339 employs an NRPS-like aminoacylation enzyme with an adenylation domain tolerant of different amino acid substrates (i.e., Val, Leu, Ile, Pro, Ser, Thr, and homo-Ala).
A preliminary assessment of the noonindole biosynthetic gene cluster (BGC) suggests a biogenetic relationship linking 5–14 and inclusive of the minor co-metabolites i–viii starting with emindole SB (14) undergoing stereospecific epoxidation and ring closure to paspaline (11) followed by sequential oxidation to paspaline B (12) and the carboxylic acid 13, followed by decarboxylation and oxidation to paxilline (1) (Figure 9). Oxidation of 1 could then yield noonindole F (10) with further oxidation and/or amino acid acylation returning noonindoles A–E (5–9) and co-clustering minor analogues (i–viii). Consistent with this hypothesis, close examination of the CMB-M0339 D400 extract GNPS and UPLC-DAD-MS data using single ion extraction (SIE) detected an ion with a molecular formula attributable to 1 (Figure S71).
Our investigation into the marine-derived Aspergillus noonimiae CMB-M0339 led to the discovery of noonindoles A–F (5–10) and related minor analogues (i–viii) as new examples of a rare class of fungal indole diterpene amino acid conjugate. This discovery highlights the continued capacity of fungi to provide access to new chemical space and validates molecular networking (GNPS) as an effective platform to detect, dereplicate, and prioritize new over known chemistry, and cultivation profiling (MATRIX) as a means to optimise the production. Our discovery of the noonindoles suggests the CMB-M0339 features an NRPS-like aminoacyl modifying enzyme in the noonindole biosynthetic gene cluster (BGC) capable of accommodating and incorporating multiple lipophilic amino acids. Further studies into the structure, biosynthesis, and biology of these and other CMB-M0339 indole diterpenes are ongoing, and will be reported elsewhere.

3. Materials and Methods

3.1. General Experimental Procedures

Chemicals were purchased from Sigma-Aldrich or Merck unless otherwise specified. Solvent extractions were performed using analytical-grade solvents, while HPLC, UPLC, and HPLC-MS analyses employed HPLC-grade solvents supplied by Labscan or Sigma-Aldrich and filtered/degassed through 0.45 μm polytetrafluoroethylene (PTFE) membrane prior to use. Deuterated solvents were purchased from Cambridge Isotopes (Tewksbury, MA, USA). Microorganisms were manipulated under sterile conditions in a Laftech class II biological safety cabinet and incubated in either an MMM Friocell incubator (Lomb Scientific, NSW, Australia) or an Innova 42R incubator shaker (John Morris, NSW, Australia) at 26.5 °C. Semi-preparative and preparative HPLCs were performed using Agilent 1100 series HPLC instruments with corresponding detectors, fraction collectors, and software. Analytical UPLC chromatograms were obtained on an Agilent 1290 infinity UPLC instrument equipped with a diode array multiple wavelength detector (Zorbax C8 RRHD 1.8 μm, 50 × 2.1 mm column, gradient elution at 0.417 mL/min over 2.50 min from 90% H2O/MeCN to 100% MeCN with isocratic 0.01% TFA/MeCN modifier). UPLC-QTOF analyses were performed on an Agilent 6545 Q-TOF instrument incorporating an Agilent 1290 Infinity II UHPLC (Zorbax C8 RRHD 1.8 μm, 50 × 2.1 mm column, gradient elution at 0.417 mL/min over 2.5 min from 90% H2O/MeCN to 100% MeCN with isocratic 0.1% formic acid/MeCN modifier). Chiroptical measurements ([α]D) were obtained on a JASCO P-1010 polarimeter in a 100 × 2 mm cell at specified temperatures. Nuclear magnetic resonance (NMR) spectra were acquired on a Bruker Avance 600 MHz spectrometer with either a 5 mm PASEL 1H/D-13C Z-Gradient probe or 5 mm CPTCI 1H/19F-13C/15N/DZ-Gradient cryoprobe, controlled by TopSpin 2.1 software, at 25 °C in either methanol-d4, CDCl3, or DMSO-d6, with referencing to residual 1H or 13C solvent resonances (methanol-d4: δH 3.31 and δC 49.15; CDCl3: δH 7.24 and δC 77.23; DMSO-d6: δH 2.50 and δC 39.50). High-resolution ESIMS spectra were obtained on a Bruker micrOTOF mass spectrometer by direct injection in MeOH at 3 μL/min using sodium formate clusters as an internal calibrant. Structural assignments were made with additional information from gCOSY, gHSQC, and gHMBC experiments.

3.2. Fungal Isolation and DNA Taxonomic Analysis

A marine sediment collected in 2008 from a location off Perth, Western Australia, was used to inoculate an M1 agar plate (inclusive of 3.3% artificial sea salt) which was incubated at 27 °C for 10–14 days, after which colony selection yielded an array of isolates including fungus CMB-M0339. Genomic DNA was extracted from the mycelia of CMB-M0339 using the DNeasy Plant Mini Kit (Qiagen) as per the manufacturers protocol, and the 18s rRNA genes were amplified by PCR using the universal primers ITS-1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS-4 (5′-TCCTCCGCTTATTGATATGC-3′) purchased from Sigma-Aldrich. The PCR mixture (50 μL) containing 1 μL of genomic DNA (20–40 ng), 200 μM of each deoxynucleoside triphosphate (dNTP), 1.5 mM MgCl2, 0.3 μM of each primer, 1 U of Taq DNA polymerase (Fisher Biotec), and 5 μL of PCR buffer was amplified using the following conditions: initial denaturation at 95 °C for 3 min, 30 cycles in series of 94 °C for 30 s (denaturation), 55 °C for 60 s (annealing), and 72 °C for 60 s (extension), followed by one cycle at 72 °C for 6 min. PCR products were purified with PCR purification kit (Qiagen, Victoria, Australia) and examined by agarose gel electrophoresis, with DNA sequencing performed by the Australian Genome Research Facility (AGRF) at The University of Queensland. A BLAST analysis (NCBI database) on the resulting CMB-M0339 ITS gene sequence (Figures S1–S3, GenBank accession no. OP132523) revealed 92.5% identity with the fungal strain Aspergillus noonimiae.

3.3. Global Natural Product Social (GNPS) Molecular Networking

Aliquots (1 μL) of CMB-M0339 cultivation extract (100 μg/mL in MeOH) were analysed on an Agilent 6545 Q-TOF LC/MS equipped with an Agilent 1290 Infinity II UPLC system (Zorbax C8, 0.21 μm, 1.8 × 50 mm column, gradient elution at 0.417 mL/min over 2.5 min from 90% H2O/MeCN to MeCN with an isocratic 0.1% formic acid/MeCN modifier). UPLC-QTOF-(+) MS/MS data acquired for all samples at a collision energy of 35 eV were converted from Agilent MassHunter data files (d) to mzXML file format using MSConvert software, and transferred to the GNPS server (gnps.ucsd.edu). Molecular networking was performed using the GNPS data analysis workflow [45] employing the spectral clustering algorithm with a cosine score of 0.5 and a minimum of 6 matched peaks. The resulting spectral network was imported into Cytoscape version 3.7.1 [47] and visualized using a ball-and-stick layout where nodes represent parent mass and cosine score was reflected by edge thickness. Moreover, group abundances were set as pie charts, which reflected the intensity of MS signals. MS/MS fragmentation analysis was performed on the same machine for ion detected in the full scan range at an intensity above 1000 counts at ten scans/s, with an isolation width of 4~m/z using fixed collision energy and a maximum of 3 selected precursors per cycle. General instrument parameters including gas temperature at 325 °C, drying gas 10 L/min, nebulizer 20 psig, sheath gas temperature 400 °C, fragmentation Volta 180eV, and skimmer 45 eV.

3.4. MATRIX Cultivation Profiling

The fungus CMB-M0339 was cultured in a 24-well plate microbioreactor under ×11 different media for 10–14 days in solid phase (27 °C), as well as in static (30 °C) and shaken broths (30 °C, 190 rpm) [46], with regular monitoring of growth (Figure S7). At this point, wells were individually extracted with EtOAc (2 mL), and the organic phase was centrifuged (13,000 rpm, 3 min) and dried under N2 at 40 °C to yield ×33 extracts. Individual extracts were redissolved in MeOH (30 μL) containing calibrant (2,4-dinitrophenoldecane ether, 50 μg/mL), and aliquots (1 μL) were subjected to: (i) UPLC-DAD analysis (Zorbax C8 1.8 μm, 2.1 × 50 mm column, gradient elution at 0.417 mL/min over 2.52 min from 90% H2O/MeCN to 100% MeCN followed by 0.83 min isocratic elution with MeCN, inclusive of an isocratic 0.01% TFA/MeCN modifier) (Figure S8); and (ii) GNPS analysis (Figure 3). This process identified solid phase D400 as the optimal culture conditions for producing targeted CMB-M0339 natural products.

3.5. Scale Up Cultivation and Fractionation

The fungus CMB-M0339 was cultivated on D400 agar (×300 plates) at 27 °C for 10–14 days after which the agar and fungal mycelia were harvested and extracted with EtOAc (2 × 5 L), and the combined organic phase was filtered and concentrated in vacuo at 40 °C to yield an extract (2.9 g). This extract was sequentially triturated with n-hexane (20 mL), CH2Cl2 (20 mL), MeOH (20 mL), and concentrated in vacuo to afford n-hexane (961.8 mg), CH2Cl2 (1783.8 mg), and MeOH (80.3 mg) soluble fractions. A portion of the CH2Cl2 soluble fraction (1363 mg) was subjected to preparative reversed-phase HPLC (Phenomenex Luna-C8 10 μm, 21.2 × 250 mm column, with gradient elution at 20 mL/min over 20 min from 90% H2O/MeCN to 100% MeCN with constant 0.1% TFA/MeCN modifier) to yield noonindole A (5) (Rf 15.7 min, 83.5 mg, 4.3%). The remaining mixed fractions were subjected to semi-preparative reversed-phase HPLC to yield noonindole B (6) (Rf 18.3 min, 2.0 mg, 0.1%) (semi-preparative HPLC (Zorbax C8 5mm column, 9.4 × 250 mm, 3 mL/min isocratic elution of 37% MeCN/H2O over 20 min with constant 0.1% TFA modifier)); noonindole F (10) (Rf 19.9 min, 0.7 mg, 0.03%) (semi-preparative HPLC (Agilent C8-Ep 5mm column, 9.4 × 250 mm, 3 mL/min isocratic elution of 50% MeCN/H2O over 25 min with constant 0.1% TFA modifier)); noonindole D (8) (Rf 28.6 min, 0.4 mg, 0.02%) (semi-preparative HPLC (Zorbax C18 5mm column, 9.4 × 250 mm, 3 mL/min isocratic elution of 40% MeCN/H2O over 30 min with constant 0.1% TFA modifier)); noonindole E (9) (Rf 20.9 min, 0.8 mg, 0.04%) (semi-preparative HPLC (Zorbax C18 5mm column, 9.4 × 250 mm, 3 mL/min isocratic elution of 40% MeCN/H2O over 30 min with constant 0.1% TFA modifier)); 12-demethylpaspaline-12-carboxylic acid (13) (Rf 9.8 min, 1.6 mg, 0.08%) (semi-preparative HPLC (Zorbax C18 5mm column, 9.4 × 250 mm, 3 mL/min isocratic elution of 85% MeCN/H2O over 15 min with constant 0.1% TFA modifier)); paspaline B (12) (Rf 26.1 min, 0.3 mg, 0.01%) (semi-preparative HPLC (Agilent C8-Ep 5mm column, 9.4 × 250 mm, 3 mL/min isocratic elution of 60% MeCN/H2O over 25 min with constant 0.1% TFA modifier)); paspaline (11) (Rf 17.8 min, 1.2 mg, 0.06%) (Semi-preparative HPLC (Agilent CN 5mm column, 9.4 × 250 mm, 3 mL/min isocratic elution of 60% MeCN/H2O over 20 min with constant 0.1% TFA modifier)); emindole SB (14) (Rf 19.7 min, 1.2 mg, 0.06%) (semi-preparative HPLC (Agilent CN 5mm column, 9.4 × 250 mm, 3 mL/min isocratic elution of 60% MeCN/H2O over 20 min with constant 0.1% TFA modifier)); and solid-phase extraction (Sep-Pak (Agilent Bond Elut C18 cartridge, 5 g) gradient elution from 90% H2O/MeCN to 100% MeCN) and semi-preparative reversed-phase HPLC (Zorbax C8 5mm column, 9.4 × 250 mm, 3 mL/min isocratic elution of 40% MeCN/H2O over 20 min with constant 0.1% TFA modifier) to yield noonindole C (7) (Rf 21.9 min, 2.0 mg, 0.1%) (Figure S9). (Note: All % yields are weight to weight estimates based on unfractionated EtOAc extract).

3.6. Characterization of Metabolites 5–14

  • noonindole A (5); pale yellow solid; [α]D21–18 (c 0.02, MeOH); NMR (600 MHz, methanol-d4), see Table S2 and Figures S10–S15; HRMS (ESI) m/z: [M+H]+ calcd for C34H47N2O6 579.3429; found 579.3456.
  • noonindole B (6); white solid; [α]D21–13 (c 0.08, MeOH); NMR (600 MHz, methanol-d4), see Table S3 and Figures S17–S22; HRMS (ESI) m/z: [M+H]+ calcd for C33H45N2O6, 565.3272; found 565.3292.
  • noonindole C (7); white solid; [α]D21–9 (c 0.06, MeOH); NMR (600 MHz, methanol-d4), see Table S4 and Figures S24–S29; HRMS (ESI) m/z [M+H]+ calcd for C35H49N2O6, 593.3585; found 593.3611.
  • noonindole D (8); white solid; [α]D23–30 (c 0.03, MeOH); NMR (600 MHz, methanol-d4), see Table S5 and Figures S31–S35; HRMS (ESI) m/z [M+H]+ calcd for C33H45N2O6, 565.3272; found 565.3287.
  • noonindole E (9); white solid; [α]D23–13 (c 0.06, MeOH); NMR (600 MHz, methanol-d4), see Table S6 and Figures S37–S41; HRMS (ESI) m/z [M+H]+ calcd for C34H45N2O6, 577.3272; found 577.3284.
  • noonindole F (10); white solid; [α]D21–18 (c 0.02, MeOH); NMR (600 MHz, methanol-d4), see Table S7 and Figures S43–S48; HRMS (ESI) m/z [M+Na]+ calcd for C27H33NO5Na, 474.2251; found 474.2262.
  • paspaline (11); white solid; [α]D22–21 (c 0.09, CHCl3); [24] NMR (600 MHz, DMSO-d6), see Table S8 and Figures S50–S53; [24] HRMS (ESI) m/z [M+H]+ calcd for C28H40NO2, 422.3054; found 422.3071.
  • paspaline B (12) white solid; [α]D22–24 (c 0.02, CHCl3); [18] NMR (600 MHz, CDCl3), see Table S9 and Figures S55–S58; [18] HRMS (ESI) m/z [M+Na]+ calcd for C28H37NO3Na, 458.2666; found 458.2680.
  • 12-demethylpaspaline-12-carboxylic acid (13); white solid; [α]D22 + 37 (c 0.01, CHCl3); [24] NMR (600 MHz, DMSO-d6), see Table S10 and Figures S60–S63; [24] HRMS (ESI) m/z [M+H]+ calcd for C28H38NO4,452.2795; found 452.2807.
  • emindole SB (14); white solid; [α]D21–18 (c 0.05, CHCl3); [24] NMR (600 MHz, DMSO-d6), see Table S11 and Figures S65–S68; [24] HRMS (ESI) m/z [M+H]+ calcd for C28H40NO, 406.3104; found 406.3126.

3.7. Phylogenetic Comparison of CMB-M0339 with Fungi Reported to Produce Biosynthetically Related Indole Terpenes

Phylogenetic tree obtained by PhyML Maximum Likelihood analysis was constructed using the top similar 18S rRNA sequences displayed after BLAST on Refseq RNA NCBI database using CMB-M0339 18S rRNA as queries (Figure S4). The JC69 model was used to infer phylogeny sequences [48]. Sequence alignments were produced with the MUSCLE program [49]. Phylogenetic tree was constructed using the UGENE program using the aforementioned models and visualized using Ugene’s tree view [50].

3.8. UPLC-QTOF-SIE Detection of 5–14 in CMB-M0339 Extract

The EtOAc extract of a CMB-M0339 D400 agar culture was dissolved in MeOH and subjected to UPLC-QTOF analysis with single ion extraction (SIE) analysis (Figure S70).

3.9. X-ray Crystallography

Crystals of 5 were obtained by slow evaporation from 50% DCM/Hexane in the cold room (−4 °C). Crystallographic data (Cu Kα, 2θmax = 125°) for 5 were collected on an Oxford Diffraction Gemini S Ultra CCD diffractometer with the crystal cooled to 190 K with an Oxford Cryosystems Desktop Cooler. Data reduction and empirical absorption corrections were carried out with the CrysAlisPro program. The structure was solved with SHELXT and refined with SHELXL [51]. The thermal ellipsoid diagrams were generated with Mercury [52]. All calculations were carried out within the WinGX graphical user interface [53]. The disordered water molecules in the structure were modelled with SQUEEZE implemented in PLATON [54]. The crystal data for 5 in CIF format were deposited in the CCDC database (2206901) (Table S13).

3.10. Antifungal Assay

The fungus Candida albicans ATCC 10231 was streaked onto a LB (Luria–Bertani) agar plate and was incubated at 37 °C for 48 h, after which a colony was transferred to fresh LB broth (15 mL) and the cell density was adjusted to 104–105 CFU/mL. Test compounds were dissolved in DMSO and diluted with H2O to prepare 600 µM stock solutions (20% DMSO), which were serially diluted with 20% DMSO to provide concentrations from 600 µM to 0.2 µM in 20% DMSO. An aliquot (10 µL) of each dilution was transferred to a 96-well microtiter plate and freshly prepared fungal broth (190 µL) was added to prepare final concentrations of 30–0.01 µM in 1% DMSO. The plates were incubated at 27 °C for 48 h and the optical density of each well was measured spectrophotometrically at 600 nm using POLARstar Omega plate (BMG LABTECH, Offenburg, Germany). Amphotericin B was used as the positive control (40 µg/mL in 10% DMSO). The IC50 value was calculated as the concentration of the compound or antibiotic required for 50% inhibition of the bacterial cells using Prism 7.0 (GraphPad Software Inc., La Jolla, CA, USA). See Figure S80.

3.11. Antibacterial Assay

The bacterium to be tested was streaked onto an LB agar plate and was incubated at 37 °C for 24 h, after which a colony was transferred to fresh LB broth (15 mL) and the cell density was adjusted to 104–105 CFU/mL. Test compounds were dissolved in DMSO and diluted with H2O to give 600 µM stock solutions (20% DMSO), which were serially diluted with 20% DMSO to prepare concentrations from 600 µM to 0.2 µM in 20% DMSO. An aliquot (10 µL) of each dilution was transferred to a 96-well microtiter plate and freshly prepared microbial broth (190 µL) was added to provide final concentrations of 30–0.01 µM in 1% DMSO. The plates were incubated at 37 °C for 24 h and the optical density of each well was measured spectrophotometrically at 600 nm using POLARstar Omega plate (BMG LABTECH, Offenburg, Germany). Each test compound was screened against the Gram-negative bacterium Escherichia coli ATCC 11775 and the Gram-positive bacteria Staphylococcus aureus ATCC 25923 and Bacillus subtilis ATCC 6633. Rifampicin was used as the positive control (40 µg/mL in 10% DMSO) for Gram-positive bacteria and a mixture of rifampicin and ampicillin was used as the positive control for Gram-negative bacteria. The IC50 value was calculated as the concentration of the compound or antibiotic required for 50% inhibition of the bacterial cells using Prism 7.0 (GraphPad Software Inc., La Jolla, CA, USA). See Figure S80.

3.12. Cytotoxicity Assays

Human colorectal (SW620) and lung carcinoma (NCI-H460) cells were seeded evenly in a 96-well micro-plate (2000 cells/well in 180 μL of RPMI 1640 medium (Roswell Park Memorial Institute medium) supplemented with 10% FBS (Fetal Bovine Serum)) and the plate was incubated for 18 h (37 °C; 5% CO2) to allow cells to attach. Test compounds were dissolved in 5% DMSO (v/v) and dilutions were generated from 300 μM to 300 nM. Aliquots (20 μL) of each dilution (or 5% aqueous DMSO for negative control and 5% aqueous SDS for positive control) were added to the plate in duplicate. After 68 h of incubation (37 °C; 5% CO2), a solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, USA) in PBS (Phosphate Buffered Saline) was added to each well to a final concentration of 0.4 mg/mL and plates were incubated for a further 4 h (37 °C; 5% CO2) after which the medium was carefully aspirated and precipitated formazan crystals were dissolved in DMSO (100 μL/well). The absorbance of each well at 580 nm was measured with a PowerWave XS Microplate Reader from Bio-Tek Instruments Inc. (Vinooski, VT) and IC50 values were calculated as the concentration of the compound required for 50% inhibition of the cancer cells using Prism 5.0 from GraphPad Software Inc. (La Jolla, CA, USA). See Figure S81.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/md20110698/s1, Figure S1: ITS gene sequence of CMB-M0339, Figure S2: NCBI-BLAST search of 18S rRNA sequence of CMB-M0339, Figure S3: Blast search for CMB-M0339, Figure S4: Phylogenetic tree, Figure S5: CMB-M0339 cultivated on SD agar, Figure S6: UPLC-DAD chromatograms of crude extract of CMB-M0339, Figure S7: CMB-M0339 cultivated under MATRIX conditions, Figure S8: UPLC-DAD chromatograms of MATRIX extracts, Figure S9: Isolation scheme for 5–14, Figures S10–S69: Annotated 1D and 2D NMR spectra and HRMS spectra for 5–14, Figure S70–S71: Single ion extraction of fresh crude extract from CMB-M0339 showing the presence of 5–14 and 1, Figures S72–S79: MS/MS fragmentation pattern of 5–9 and i-v, Figures S80–S81: Antimicrobial and cytotoxic activities of 5–14. Table S1: Composition of media used for cultivation profiling, Tables S2–S11: 1D and 2D NMR data for 5–14, Table S12: Predicted molecular formulae generated for 5–9 and i-viii observed in GNPS cluster, Table S13: Bond lengths and angles for X-ray crystal structure of 5. Refs. [18,24] are cited in the Supplementary Materials.

Author Contributions

R.J.C. conceptualized the research; S.K. carried out the isolation, spectroscopic characterization, crystallization, and antibacterial, antifungal and cytotoxicity assays; P.V.B. performed the X-ray analyses; S.K. and Z.G.K. performed the taxonomic identification of the fungal strain; assigned molecular structures, and constructed the supplementary material; R.J.C. reviewed all data and drafted the manuscript, with support from S.K. and Z.G.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded in part by the Institute for Molecular Bioscience, The University of Queensland.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Raw NMR data is available at https://npmrd-project.org/ (access on 26 September 2022).

Acknowledgments

We thank R. Ritesh for isolation of CMB-M0339. S. K. thanks The University of Queensland for an International Postgraduate Scholarship.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Springer, J.P.; Clardy, J.; Wells, J.M.; Cole, R.J.; Kirksey, J.W. The structure of paxilline, a tremorgenic metabolite of Penicillium paxilli bainier. Tetrahedron Lett. 1975, 16, 2531–2534. [Google Scholar] [CrossRef]
  2. Mantle, P.G.; Weedon, C.M. Biosynthesis and transformation of tremorgenic indolediterpenoids by Penicillium paxilli and Acremonium lolii. Phytochemistry 1994, 36, 1209–1217. [Google Scholar] [CrossRef]
  3. Huang, X.-H.; Tomoda, H.; Nishida, H.; Masuma, R.; Omura, S. Terpendoles, novel ACAT inhibitors produced by Albophoma yamanashiensis. I. Production, isolation and biological properties. J. Antibiot. 1994, 48, 1–4. [Google Scholar] [CrossRef] [PubMed]
  4. Huang, X.H.; Nishida, H.; Tomoda, H.; Tabata, N.; Shiomi, K.; Yang, D.J.; Takayanagi, H.; Omura, S. Terpendoles, novel ACAT inhibitors produced by Albophoma yamanashiensis. II. Structure elucidation of terpendoles A, B, C and D. J. Antibiot. 1995, 48, 5–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Tomoda, H.; Tabata, N.; Yang, D.-J.; Takayanagi, H.; Omura, S. Terpendoles, Novel ACAT inhibitors produced by Albophoma yamanashiensis. III. Production, isolation and structure eucidation of new components. J. Antibiot. 1995, 48, 793–804. [Google Scholar] [CrossRef]
  6. Gallagher, R.T.; Clardy, J.; Wilson, B.J. Aflatrem, a tremorgenic toxin from Aspergillus flavus. Tetrahedron Lett. 1980, 21, 239–242. [Google Scholar] [CrossRef]
  7. Gallagher, R.T.; Wilson, B.J. Aflatrem, the tremorgenic mycotoxin from Aspergillus flavus. Mycopathologia 1979, 66, 183–185. [Google Scholar] [CrossRef]
  8. Laakso, J.A.; Gloer, J.B.; Wicklow, D.T.; Dowd, P.F. Sulpinines A–C and secopenitrem B: New antiinsectan metabolites from the sclerotia of Aspergillus sulphureus. J. Org. Chem. 1992, 57, 2066–2071. [Google Scholar] [CrossRef]
  9. Staub, G.M.; Gloer, K.B.; Gloer, J.B.; Wicklow, D.T.; Dowd, P.F. New paspalinine derivatives with antiinsectan activity from the sclerotia of Aspergillus nomius. Tetrahedron Lett. 1993, 34, 2569–2572. [Google Scholar] [CrossRef]
  10. Junker, B.; Walker, A.; Connors, N.; Seeley, A.; Masurekar, P.; Hesse, M. Production of indole diterpenes by Aspergillus alliaceus. Biotechnol. Bioeng. 2006, 95, 919–937. [Google Scholar] [CrossRef]
  11. Bills, G.F.; Polishook, J.D.; Goetz, M.A.; Sullivan, R.F.; White, J.F. Chaunopycnis pustulata sp. nov., a new clavicipitalean anamorph producing metabolites that modulate potassium ion channels. Mycol. Prog. 2002, 1, 3–17. [Google Scholar] [CrossRef]
  12. Springer, J.P.; Clardy, J. Paspaline and paspalicine, two indole-mevalonate metabolites from Claviceps paspalli. Tetrahedron Lett. 1980, 21, 231–234. [Google Scholar] [CrossRef]
  13. Nozawa, K.; Nakajima, S.; Kawai, K.; Udagawa, S. Isolation and structures of indoloditerpenes, possible biosynthetic intermediates to the tremorgenic mycotoxin, paxilline, from Emericella striata. J. Chem. Soc. Perkin Trans. 1 1988, 2607–2610. [Google Scholar] [CrossRef]
  14. Nozawa, K.; Horie, Y.; Udagawa, S.; Kawai, K.; Yamazaki, M. Isolation of new tremorgenic indolediterpene, 1′-O-acetylpaxilline, from Emericella striata and distribution of paxilline in Emericella sp. Chem. Pharm. Bull. 1989, 37, 1387–1389. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Belofsky, G.N.; Gloer, J.B.; Wicklow, D.T.; Dowd, P.F. Antiinsectan alkaloids: Shearinines A–C and a new paxilline derivative from the ascostromata of Eupenicillium shearii. Tetrahedron 1995, 51, 3959–3968. [Google Scholar] [CrossRef]
  16. Gatenby, W.A.; Munday-Finch, S.C.; Wilkins, A.L.; Miles, C.O. Terpendole M, a novel indole-diterpenoid isolated from Lolium perenne infected with the endophytic fungus Neotyphodium lolii. J. Agric. Food. Chem. 1999, 47, 1092–1097. [Google Scholar] [CrossRef]
  17. De Jesus, A.E.; Steyn, P.S.; Van Heerden, F.R.; Vleggaar, R.; Wessels, P.L.; Hull, W.E. Structure and biosynthesis of the penitrems A–F, six novel tremorgenic mycotoxins from Penicillium crustosum. J. Chem. Soc. Chem. Commun. 1981, 6, 289–291. [Google Scholar] [CrossRef]
  18. Munday-Finch, S.C.; Wilkins, A.L.; Miles, C.O. Isolation of paspaline B, an indole-diterpenoid from Penicillium paxilli. Phytochemistry 1996, 41, 327–332. [Google Scholar] [CrossRef]
  19. Itabashi, T.; Hosoe, T.; Wakana, D.; Fukushima, K.; Takizawa, K.; Yaguchi, T.; Okada, K.; Takaki, G.M.C.; Kawai, K. A new indoloditerpene derivative, penijanthine A, isolated from Penicillium janthinellum. J. Nat. Med. 2009, 63, 96–99. [Google Scholar] [CrossRef]
  20. Ariantari, N.P.; Ancheeva, E.; Wang, C.; Mandi, A.; Kendel, T.O.; Kurtan, T.; Chaidir, C.; Muller, W.E.G.; Kassack, M.U.; Janiak, C.; et al. Indole diterpenoids from an endophytic Penicillium sp. J. Nat. Prod. 2019, 82, 1412–1423. [Google Scholar] [CrossRef]
  21. Yu, J.; Wang, J.-P.; Liu, S.-F.; Yin, C.-Y.; Tang, D.-Y.; Li, Y.-H.; Zhang, L.-X. 7-Methoxy-13-dehydroxypaxilline: New indole diterpenoid from an endophytic fungus Penicillium sp. Nb 19. Nat. Prod. Res. 2022, 1–9. [Google Scholar] [CrossRef]
  22. Bills, G.F.; Giacobbe, R.A.; Lee, S.H.; Pelaez, F.; Tkacz, J.S. Tremorgenic mycotoxins, paspalitrem A and C, from a tropical Phomopsis. Mycol. Res. 1992, 96, 977–983. [Google Scholar] [CrossRef]
  23. Sallam, A.A.; Houssen, W.E.; Gissendanner, C.R.; Orabi, K.Y.; Foudah, A.I.; Sayed, K.A.E. Bioguided discovery and pharmacophore modeling of the mycotoxic indole diterpene alkaloids penitrems as breast cancer proliferation, migration, and invasion inhibitors. Med. Chem. Comm. 2013, 4, 1360–1369. [Google Scholar] [CrossRef] [PubMed]
  24. Fan, Y.; Wang, Y.; Liu, P.; Fu, P.; Zhu, T.; Wang, W.; Zhu, W. Indole-diterpenoids with anti-H1N1 activity from the aceduric fungus Penicillium camemberti OUCMDZ-1492. J. Nat. Prod. 2013, 76, 1328–1336. [Google Scholar] [CrossRef] [PubMed]
  25. Zhou, L.-M.; Kong, F.-D.; Li, J.-H.; Zheng, H.-Z.; Dai, H.-F.; Luo, D.-Q.; Zhao, Y.-X. Indole-diterpenoids with protein tyrosine phosphatase inhibitory activities from the marine-derived fungus Penicillium sp. KFD28. J. Nat. Prod. 2019, 82, 2638–2644. [Google Scholar] [CrossRef] [PubMed]
  26. Chen, M.Y.; Xie, Q.Y.; Kong, F.D.; Ma, Q.Y.; Zhou, L.M.; Yuan, J.Z.; Dai, H.F.; Wu, Y.G.; Zhao, Y.X. Two new indole-diterpenoids from the marine derived fungus Penicillium sp. KFD28. J. Asian Nat. Prod. Res. 2020, 23, 1030–1036. [Google Scholar] [CrossRef] [PubMed]
  27. Dai, L.-T.; Yang, L.; Kong, F.-D.; Ma, Q.-Y.; Xie, Q.-Y.; Dai, H.-F.; Yu, Z.-F.; Zhao, Y.-X. Cytotoxic indole-diterpenoids from the marine-derived fungus Penicillium sp. KFD28. Mar. Drugs 2021, 19, 613. [Google Scholar] [CrossRef] [PubMed]
  28. Knaus, H.; McManus, O.W.; Lee, S.H.; Schmalhofer, W.A.; Garcia-Calvo, M.; Helms, L.M.H.; Sanchez, M.; Giangiacomo, K.; Reuben, J.P.; Smith, A.B.; et al. Tremorgenic indole alkaloids potently inhibit smooth muscle high-conductance calcium-activated potassium channels. Biochemistry 1994, 33, 5819–5828. [Google Scholar] [CrossRef]
  29. Sallam, A.A.; Ayoub, N.M.; Foudah, A.I.; Gissendanner, C.R.; Meyer, S.A.; Sayed, K.A.E. Indole diterpene alkaloids as novel inhibitors of the Wnt/β-catenin pathway in breast cancer cells. Eur. J. Med. Chem. 2013, 70, 594–606. [Google Scholar] [CrossRef] [Green Version]
  30. Garcia, M.L.; Giacobbe, R.A.; Hensens, O.D.; Lee, S.H.; McManus, O.B.; Zink, D.L. Indole diterepene alkaloid compounds. Patent EP 0 804 186 B1, 20 January 1995. [Google Scholar]
  31. Goetz, M.A.; Kaczorowski, G.J.; Monaghan, R.L.; Strohl, W.R.; Tkacz, J.S. Novel Maxi-K Channel Blockers, Methods of Use and Process for Making the Same. Patent WO 03/105868 A1, 24 December 2003. [Google Scholar]
  32. Zhou, Y.; Xia, X.-M.; Lingle, C.J. The functionally relevant site for paxilline inhibition of BK channels. Proc. Natl. Acad. Sci. USA 2020, 117, 1021–1026. [Google Scholar] [CrossRef]
  33. Mewshaw, R.E.; Taylor, M.D.; Smith, A.B. Indole diterpene synthetic studies. 2. First-generation total synthesis of (−)-paspaline. J. Org. Chem. 1989, 54, 3449–3462. [Google Scholar] [CrossRef]
  34. Sharpe, R.J.; Johnson, J.S. Asymmetric total synthesis of the indole diterpene alkaloid paspaline. J. Org. Chem. 2015, 80, 9740–9766. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Schatz, D.J.; Kuenstner, E.J.; George, D.T.; Pronin, S.V. Synthesis of rearranged indole diterpenes of the paxilline type. Nat. Prod. Rep. 2021, 39, 946–968. [Google Scholar] [CrossRef] [PubMed]
  36. Young, C.; McMillan, L.; Telfer, E.; Scott, B. Molecular cloning and genetic analysis of an indole-diterpene gene cluster from Penicillium paxilli. Mol. Microbiol. 2001, 39, 754–764. [Google Scholar] [CrossRef] [PubMed]
  37. Young, C.A.; Felitti, S.; Shields, K.; Spangenberg, G.; Johnson, R.D.; Bryan, G.T.; Saikia, S.; Scott, B. A complex gene cluster for indole-diterpene biosynthesis in the grass endophyte Neotyphodium lolii. Fungal. Genet. Biol. 2006, 43, 679–693. [Google Scholar] [CrossRef] [PubMed]
  38. Saikia, S.; Parker, E.J.; Koulman, A.; Scott, B. Defining paxilline biosynthesis in Penicillium paxilli functional characterization of two cytochrome p450 monooxygenases. J. Biol. Chem. 2007, 282, 16829–16837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Nicholson, M.J.; Koulman, A.; Monahan, B.J.; Pritchard, B.L.; Payne, G.A.; Scott, B. Identification of two aflatrem biosynthesis gene loci in Aspergillus flavus and metabolic engineering of Penicillium paxilli to elucidate their function. Appl. Environ. Microbiol. 2009, 75, 7469–7481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Scott, B.; Young, C.A.; Saikia, S.; McMillan, L.K.; Monahan, B.J.; Koulman, A.; Astin, J.; Eaton, C.J.; Bryant, A.; Wrenn, R.E.; et al. Deletion and gene expression analyses define the paxilline biosynthetic gene cluster in Penicillium paxilli. Toxins 2013, 5, 1422–1446. [Google Scholar] [CrossRef]
  41. Tagami, K.; Minami, A.; Fujii, R.; Liu, C.; Tanaka, M.; Gomi, K.; Dairi, T.; Oikawa, H. Rapid reconstitution of biosynthetic machinery for fungal metabolites in Aspergillus oryzae: Total biosynthesis of aflatrem. Chembiochem 2014, 15, 2076–2080. [Google Scholar] [CrossRef]
  42. Liu, C.; Tagami, K.; Minami, A.; Matsumoto, T.; Frisvad, J.C.; Suzuki, H.; Ishikawa, J.; Gomi, K.; Oikawa, H. Reconstitution of biosynthetic machinery for the synthesis of the highly elaborated indole diterpene penitrem. Angew. Chem. Int. Ed. 2015, 54, 5748–5752. [Google Scholar] [CrossRef]
  43. McLellan, R.M.; Cameron, R.C.; Nicholson, M.J.; Parker, E.J. Aminoacylation of indole diterpenes by cluster-specific monomodular NRPS-like enzymes. Org. Lett. 2022, 24, 2332–2337. [Google Scholar] [CrossRef] [PubMed]
  44. Laakso, J.A.; Tepaske, M.R.; Dowd, P.F.; Gloer, J.B.; Wicklow, D.T.; Staub, G.M. Indole antiinsectan metabolites. U.S. Patent 5227396, 13 July 1993. [Google Scholar]
  45. Wang, M.; Carver, J.J.; Phelan, V.V.; Sanchez, L.M.; Garg, N.; Peng, Y.; Nguyen, D.D.; Watrous, J.; Kapono, C.A.; Luzzatto-Knaan, T.; et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat. Biotechnol. 2016, 34, 828–837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Salim, A.A.; Khalil, Z.G.; Elbanna, A.H.; Wu, T.; Capon, R.J. Methods in microbial biodiscovery. Mar. Drugs 2021, 19, 503. [Google Scholar] [CrossRef] [PubMed]
  47. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [Google Scholar] [CrossRef] [PubMed]
  48. Yang, Z.; Goldman, N.; Friday, A. Comparison of models for nucleotide substitution used in maximum-likelihood phylogenetic estimation. Mol. Biol. Evol. 1994, 11, 316–324. [Google Scholar]
  49. Edgar, R.C. MUSCLE: A multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 2004, 5, 1–19. [Google Scholar] [CrossRef] [Green Version]
  50. Okonechnikov, K.; Golosova, O.; Fursov, M. Unipro UGENE: A unified bioinformatics toolkit. Bioinformatics 2012, 28, 1166–1167. [Google Scholar] [CrossRef] [Green Version]
  51. Sheldrick, G.M. A short history of SHELX. Acta. Crystallogr. 2008, 64, 112–122. [Google Scholar] [CrossRef] [Green Version]
  52. Macrae, C.F.; Edgington, P.R.; McCabe, P.; Pidcock, E.; Shields, G.P.; Taylor, R.; Towler, M.; Streek, J.V.D. Mercury: Visualization and analysis of crystal structures. J. App. Crystallogr. 2006, 39, 453–457. [Google Scholar] [CrossRef] [Green Version]
  53. Farrugia, L.J. WinGX suite for small-molecule single-crystal crystallography. J. App. Crystallogr. 1999, 32, 837–838. [Google Scholar] [CrossRef]
  54. Spek, A.L. Single-crystal structure validation with the program PLATON. J. App. Crystallogr. 2003, 36, 7–13. [Google Scholar] [CrossRef]
Marinedrugs 20 00698 g001 550
Figure 1. Known fungal IDTs highlighting the paxilline scaffold (blue) and rare amino acid acyl functionality (tan).
Figure 1. Known fungal IDTs highlighting the paxilline scaffold (blue) and rare amino acid acyl functionality (tan).
Marinedrugs 20 00698 g001
Marinedrugs 20 00698 g002 550
Figure 2. GNPS molecular network of an inhouse fungal extract library, revealing a unique cluster of metabolites (expansion) associated exclusively with strain CMB-M0339.
Figure 2. GNPS molecular network of an inhouse fungal extract library, revealing a unique cluster of metabolites (expansion) associated exclusively with strain CMB-M0339.
Marinedrugs 20 00698 g002
Marinedrugs 20 00698 g003 550
Figure 3. GNPS molecular network of a set of MATRIX extracts of CMB-M0339 showing production of noonindoles A–E (5–9) and related minor metabolites under selected culture conditions.
Figure 3. GNPS molecular network of a set of MATRIX extracts of CMB-M0339 showing production of noonindoles A–E (5–9) and related minor metabolites under selected culture conditions.
Marinedrugs 20 00698 g003
Marinedrugs 20 00698 g004 550
Figure 4. New noonindoles A–F (5–10) and known 11–14.
Figure 4. New noonindoles A–F (5–10) and known 11–14.
Marinedrugs 20 00698 g004
Marinedrugs 20 00698 g005 550
Figure 5. 2D NMR (methanol-d4) correlations for 5–10.
Figure 5. 2D NMR (methanol-d4) correlations for 5–10.
Marinedrugs 20 00698 g005
Marinedrugs 20 00698 g006 550
Figure 6. X-ray crystal structure of noonindole A (5).
Figure 6. X-ray crystal structure of noonindole A (5).
Marinedrugs 20 00698 g006
Marinedrugs 20 00698 g007 550
Figure 7. GNPS cluster of the EtOAc extract of a D400 (MATRIX) culture of CMB-M0339 revealing 5–9 along with closely associated nodes for the minor analogues i–viii.
Figure 7. GNPS cluster of the EtOAc extract of a D400 (MATRIX) culture of CMB-M0339 revealing 5–9 along with closely associated nodes for the minor analogues i–viii.
Marinedrugs 20 00698 g007
Marinedrugs 20 00698 g008 550
Figure 8. MS/MS fragmentations common to 1–5 and minor co-metabolites i–viii; (A) loss of water, (B) retro-Aldol loss of acetone and, (C) loss of the amino acid residue.
Figure 8. MS/MS fragmentations common to 1–5 and minor co-metabolites i–viii; (A) loss of water, (B) retro-Aldol loss of acetone and, (C) loss of the amino acid residue.
Marinedrugs 20 00698 g008
Marinedrugs 20 00698 g009 550
Figure 9. Plausible biogenetic relationship linking 5–14 (and 1) and inclusive of the minor co-metabolites i–viii.
Figure 9. Plausible biogenetic relationship linking 5–14 (and 1) and inclusive of the minor co-metabolites i–viii.
Marinedrugs 20 00698 g009
Table
Table 1. 1D NMR (methanol-d4) data for noonindoles A–C (5–7) #.
Table 1. 1D NMR (methanol-d4) data for noonindoles A–C (5–7) #.
Pos.(5)
δH, mult. (J in Hz)		 
δC		(6)
δH, mult. (J in Hz)		 
δC		(7)
δH, mult. (J in Hz)		 
δC
2-152.4-152.3-152.2
3-52.0-51.9-51.8
4-46.4-46.2-46.2
5
 		a 2.87, ddd (13.6, 13.6, 5.2)
b 1.81, br dd (13.6, 5.2)		28.1
 		a 2.88, ddd (13.5, 13.5, 5.1)
b 1.83, br dd (13.5, 5.1)		28.0
 		a 2.87, ddd (13.8, 13.8, 5.4)
b 1.84, br dd (13.8, 5.4)		27.9
 
6
 		a 2.38, m
b 1.91, m		30.6
 		a 2.39, m
b 1.93, m		30.5
 		a 2.39, m
b 1.93, m		30.5
 
74.91, m74.64.90, m74.84.92, br t (8.5)74.8
93.68, d (1.9)84.03.72, d (1.5)83.93.71, br s84.0
10-198.5-198.1-197.9
115.62, d (1.9)122.45.57, d (1.5)122.05.57, d (1.9)121.8
12-165.9-165.8-165.0
13-80.0-80.0-80.1
145.53, dd (10.2, 5.3)77.95.50, dd (10.4, 5.0)77.35.51, dd (10.4, 5.1)77.5
15
 		a 2.24, dd (11.1, 10.2)
b 2.21, m		28.5
 		a 2.25, dd (13.0, 10.4)
b 2.17, m		28.3
 		a 2.25, dd (13.2, 10.4)
b 2.20, m		28.1
 
162.92, m47.42.98, m47.52.97, m47.5
17
 		a 2.73, dd (13.0, 6.2)
b 2.47 a, m		27.6
 		a 2.74, dd (13.1, 6.3)
b 2.47, dd (13.1, 11.1)		27.6
 		a 2.74, dd (13.0, 6.3)
b 2.47, dd (13.0, 10.8)		27.6
 
18-117.4-117.3-117.2
19-126.2-126.0-126.1
207.31, d (7.5)119.07.30, d (7.9)118.87.30, d (7.8)118.9
216.94, ddd (7.5, 7.5, 1.1)120.16.93, br dd (7.9, 7.7)119.96.93, ddd (7.8, 7.8, 1.1)119.9
226.98, ddd (7.5, 7.5, 1.1)121.16.97, ddd (7.9, 7.9, 0.9)121.16.98, ddd (7.8, 7.8, 1.1)121.1
237.27, d (7.5)112.77.28, d (7.9)112.77.28, d (7.8)112.7
24-141.8-141.9-141.9
25-73.3-73.0-73.0
261.28, s25.41.28, s25.31.30, s25.5
271.26, s26.21.26, s26.41.27, s25.8
1′-167.4-168.9-168.9
2′3.86, d (5.5)74.83.90, br s68.74.02, m67.5
3′2.47 a, m
-		28.4
-		2.31, m
-		30.7
-		a 1.90, m
b 1.69, m		37.4
37.4
4′1.05 b19.41.09, br d (5.3)18.71.56, m26.2
5′1.03, d (7.1)17.00.99, d (7.0)17.70.97, d (6.4)23.4
6′----0.91, d (6.4)21.4
3-Me1.37, s16.71.37, s16.61.38, s16.6
4-Me1.04 b19.41.10, s19.51.09, br s19.4
NHMe--2.72, s33.8--
NMe22.90, s43.0--2.93, s42.1
# Data acquired on the TFA salts. a,b Resonances with the same superscript overlap and assignments can be interchanged.
Table
Table 2. 1D NMR (methanol-d4) data for noonindoles D–F (8–10).
Table 2. 1D NMR (methanol-d4) data for noonindoles D–F (8–10).
Pos.(8)
δH, mult. (J in Hz)		 
δC		(9)
δH, mult. (J in Hz)		 
δC		(10)
δH, mult. (J in Hz)		 
δC
2-151.1-152.5-152.9
3-50.5-51.9-51.8
4-44.6-46.2-44.7
5
 		a 2.87 a, m
b 1.80, m		28.0
 		a 3.28 *
b 2.36, d (6.3)		33.0
 		a 2.80, ddd (13.5, 13.5, 5.1)
b 1.79, dd (13.5, 5.1)		28.1
 
6
 		a 2.37, m
b 1.91, m		30.4
 		5.74, m
 		113.5
 		a 2.33, m
b 1.90, m		30.2
 
74.90, m74.6-146.44.88, m74.7
93.71, d (1.9)83.74.09, s87.63.78, d (1.5)84.0
10-nd-196.8-200.0
115.58, d (1.9)121.75.71, br s119.56.01, br s122.9
12-nd-nd-167.5
13-78.9-77.8-80.8
145.37, dd (10.6, 5.1)74.45.41, dd (9.8, 5.8)75.54.16, dd (10.5, 4.9)70.3
15
 		a 2.16, m
b 2.04, ddd (7.1, 5.1, 2.3)		28.4
 		2.18, m
 		30.0
 		a 2.08, dd (13.3, 10.5)
b 1.93, m		31.7
 
162.95, m47.02.90, m47.52.90, m48.0
17
 		a 2.72, dd (13.1, 6.4)
b 2.45, dd (13.1, 10.7)		27.5
 		a 2.72, dd (13.0, 6.5)
b 2.44, dd (13.0, 10.8)		28.0
 		a 2.68, dd (13.0, 6.1)
b 2.42, dd (13.0, 10.0)		27.8
 
18-116.8-117.4-117.4
19-124.7-126.2-126.2
207.30, d (7.7)118.67.30, d (7.2)119.17.29, d (7.6)118.8
216.92, ddd (7.7, 7.3, 0.9)119.66.93, m120.06.92, br dd (7.6, 7.2)119.8
226.97, ddd (8.1, 7.3, 0.9)120.76.97, m121.26.95, br dd (7.4, 7.2)120.9
237.27, d (8.1)112.47.27, d (7.5)112.87.26, d (7.4)112.7
24-140.4-142.1-141.8
25-71.6-75.6-73.2
261.28, s25.11.33, s27.1 a1.29, s25.2
271.26, s25.91.26, s27.1 a1.27, s26.2
1′-nd-nd--
2′2.87 a, m72.92.86, d (9.4)76.0--
3′
 		a 1.77, m
b 1.69, m		23.8
 		2.11, m
 		28.7
 		-
-		-
-
4′0.91, t (7.4)10.10.97, t (7.4)19.9--
5′--0.97, t (7.4)19.9--
3-Me1.37, s16.31.40, s16.91.32, s16.5
4-Me1.08, s19.41.14, s21.01.04, s19.6
NMe22.26, s43.42.34, s42.4--
nd: Not detected. a Resonances with the same superscript within a column are overlapping. * Obscured by residual solvent resonance. # Data for 8–9 acquired on the free bases (not TFA salts).
Table
Table 3. Comparison of 5–9 and minor co-metabolites i–viii.
Table 3. Comparison of 5–9 and minor co-metabolites i–viii.
Marinedrugs 20 00698 i001
X (ester)(a)(b)(c)
N,N-dimethyl-valine(5)(9)(viii)
N-methyl-valine(6)--
N,N-dimethyl-leucine(7)(vii)(vi)
N,N-dimethyl-homoalanine(8)--
N,N-dimethyl-alanine A(i)--
N,N-dimethyl-serine B(ii)--
N,N-dimethyl-threonine(iii)--
N-methyl-proline C(iv)--
N,N-dimethyl-isoleucine D(v)--
(a,b,c) Proposed hexacyclic scaffolds. Possible alternate isomers: A N-methyl-homoalanine, valine; B N-methyl-threonine; C pipecolic acid; D N,N-dimethyl-allo-isoleucine.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kankanamge, S.; Khalil, Z.G.; Bernhardt, P.V.; Capon, R.J. Noonindoles A–F: Rare Indole Diterpene Amino Acid Conjugates from a Marine-Derived Fungus, Aspergillus noonimiae CMB-M0339. Mar. Drugs 2022, 20, 698. https://doi.org/10.3390/md20110698

AMA Style

Kankanamge S, Khalil ZG, Bernhardt PV, Capon RJ. Noonindoles A–F: Rare Indole Diterpene Amino Acid Conjugates from a Marine-Derived Fungus, Aspergillus noonimiae CMB-M0339. Marine Drugs. 2022; 20(11):698. https://doi.org/10.3390/md20110698

Chicago/Turabian Style

Kankanamge, Sarani, Zeinab G. Khalil, Paul V. Bernhardt, and Robert J. Capon. 2022. "Noonindoles A–F: Rare Indole Diterpene Amino Acid Conjugates from a Marine-Derived Fungus, Aspergillus noonimiae CMB-M0339" Marine Drugs 20, no. 11: 698. https://doi.org/10.3390/md20110698

APA Style

Kankanamge, S., Khalil, Z. G., Bernhardt, P. V., & Capon, R. J. (2022). Noonindoles A–F: Rare Indole Diterpene Amino Acid Conjugates from a Marine-Derived Fungus, Aspergillus noonimiae CMB-M0339. Marine Drugs, 20(11), 698. https://doi.org/10.3390/md20110698

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop